Suppr超能文献

群体驱虫计划的经济学

Economics of Mass Deworming Programs

作者信息

Ahuja Amrita, Baird Sarah, Hicks Joan Hamory, Kremer Michael, Miguel Edward

Abstract

Soil-transmitted helminth (STH) and schistosomiasis infections affect more than 1 billion people, mainly in low- and middle-income countries, particularly school-age children. Although light infections can be fairly asymptomatic, severe infections can have significant health effects, such as malnutrition, listlessness, organ damage, and internal bleeding (Bundy, Appleby, and others 2017). Low-cost drugs are available and are the standard of medical care for diagnosed infections. Because diagnosis is relatively expensive, and treatment is inexpensive and safe, the World Health Organization (WHO) recommends periodic mass treatments in areas where worm infections are greater than certain thresholds (WHO 2015). A number of organizations, including the Copenhagen Consensus, GiveWell, and the Abdul Latif Jameel Poverty Action Lab, which have reviewed the evidence for, and comparative cost-effectiveness of, a wide range of development interventions, have consistently ranked deworming as a priority for investment. However, Taylor-Robinson and others (2015) challenge this policy, accepting that those known to be infected should be treated but arguing that there is substantial evidence that mass drug administration (MDA) has no impact on a range of outcomes. This chapter discusses the economics of policy choices surrounding public investments in deworming and considers policy choices under two frameworks: Individuals are presumed to make decisions that maximize their own welfare, but government intervention may be justified in cases in which individual actions create externalities for others. These externalities could include health externalities from reductions in the transmission of infectious disease, as well as fiscal externalities if treatment increases long-term earnings and tax payments. Evidence on epidemiological and fiscal externalities from deworming will be important for informing decisions under this perspective. Policy makers should pursue a policy if the statistical expectation of the value of benefits exceeds the cost. Future monetary benefits should be discounted back to the present. Policy makers may also value nonfinancial goals, such as weight gain or school participation; they should pursue a policy if the statistical expectation of the benefit achieved per unit of expenditure exceeds that of other policies that policy makers are considering. Under either framework, the case for government subsidies will be stronger if demand for deworming is sensitive to price. If everyone would buy deworming medicine on their own, without subsidies, then subsidies would yield no benefits; they would generate a deadweight loss of taxation. The first perspective focuses on individual goals and assumes that consumers will maximize their own welfare. It treats them as rational and informed, and it abstracts from intrahousehold conflicts. The second perspective does not make these assumptions and seeks simply to inform policy makers about expected benefit-cost ratios or cost-effectiveness metrics, rather than making welfare statements. This chapter summarizes the public finance case for deworming subsidies, given the evidence on epidemiological externalities and high responsiveness of household deworming to price. It reviews the evidence on the cost-effectiveness of mass school-based deworming and associated fiscal externalities. It argues that the expected benefits of following the WHO’s recommendation of mass presumptive deworming of children in endemic regions exceed the costs, even given uncertainty about the magnitude and likelihood of impacts in given contexts. This benefit is realized even when only the educational and economic benefits of deworming are considered. Finally, the chapter maintains that between the two leading policy options for treatment in endemic areas—mass treatment versus screening and treatment of those found to be infected—the former is preferred under both public finance and cost-effectiveness approaches. Definitions of age groupings and age-specific terminology used in this volume can be found in chapter 1 (Bundy, de Silva, and others 2017).

摘要

土壤传播的蠕虫(STH)感染和血吸虫病感染影响着超过10亿人,主要分布在低收入和中等收入国家,尤其是学龄儿童。虽然轻度感染可能基本没有症状,但重度感染会对健康产生重大影响,如营养不良、无精打采、器官损伤和内出血(邦迪、阿普尔比等人,2017年)。有低成本的药物可供使用,这些药物是已确诊感染的医疗护理标准。由于诊断相对昂贵,而治疗既便宜又安全,世界卫生组织(WHO)建议在蠕虫感染率超过特定阈值的地区进行定期群体治疗(WHO,2015年)。包括哥本哈根共识组织、给予网和阿卜杜勒·拉蒂夫·贾米尔贫困行动实验室在内的一些组织,审查了一系列发展干预措施的证据及其比较成本效益,一直将驱虫列为优先投资项目。然而,泰勒 - 罗宾逊等人(2015年)对这一政策提出了质疑,他们承认已知感染者应该接受治疗,但认为有大量证据表明群体药物给药(MDA)对一系列结果没有影响。本章讨论围绕公共投资驱虫的政策选择的经济学,并在两个框架下考虑政策选择:假定个人做出使其自身福利最大化的决策,但在个人行为给他人造成外部性的情况下,政府干预可能是合理的。这些外部性可能包括传染病传播减少带来的健康外部性,以及如果治疗增加长期收入和税收支付所产生的财政外部性。驱虫的流行病学和财政外部性证据对于在此视角下做出决策很重要。如果收益价值的统计预期超过成本,政策制定者就应该推行一项政策。未来的货币收益应该折算到当前。政策制定者也可能重视非财务目标,如体重增加或上学参与度;如果每单位支出所实现收益的统计预期超过政策制定者正在考虑的其他政策,他们就应该推行一项政策。在任何一个框架下,如果驱虫需求对价格敏感,政府补贴的理由就会更充分。如果每个人在没有补贴的情况下都会自行购买驱虫药,那么补贴就不会产生任何益处;补贴会造成税收的无谓损失。第一个视角关注个人目标,并假定消费者会使其自身福利最大化。它将他们视为理性且信息充分的,并且忽略家庭内部冲突。第二个视角不做这些假设,只是试图向政策制定者通报预期的效益成本比或成本效益指标,而不是做出福利陈述。鉴于关于流行病学外部性的证据以及家庭驱虫对价格的高反应性,本章总结了驱虫补贴的公共财政理由。它审查了基于学校的群体驱虫的成本效益及相关财政外部性的证据。本章认为,即使考虑到在特定情况下影响的程度和可能性存在不确定性,遵循WHO关于在流行地区对儿童进行群体推定驱虫的建议所带来的预期收益也超过成本。即使仅考虑驱虫的教育和经济效益,这种收益也能实现。最后,本章坚持认为,在流行地区治疗的两种主要政策选择——群体治疗与对已发现感染者进行筛查和治疗——中,在前述公共财政和成本效益方法下,前者更可取。本卷中使用的年龄分组定义和特定年龄术语可在第1章中找到(邦迪、德席尔瓦等人,2017年)。

相似文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验